Manufacturers report positive results for efgartigimod for myasthenia gravis in late-stage trial

In the phase III ADAPT trial, more patients taking this antibody Fc fragment that blocks IgG recycling and increases clearance of disease-causing antibodies met primary endpoint of percentage of responderson the MG-ADL score (67.7% vs 29.7% placebo).


Biospace Inc.